Intravitreal anti-vascular endothelial growth factor injections to treat post-trabeculectomy Swan syndrome.
Anti-vascular endothelial growth factors
Swan syndrome
Trabeculectomy
Wound neovascularization
Journal
American journal of ophthalmology case reports
ISSN: 2451-9936
Titre abrégé: Am J Ophthalmol Case Rep
Pays: United States
ID NLM: 101679941
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
21
01
2021
revised:
10
03
2021
accepted:
20
01
2022
entrez:
11
2
2022
pubmed:
12
2
2022
medline:
12
2
2022
Statut:
epublish
Résumé
To report a case of wound neovascularization (Swan syndrome) one year after trabeculectomy favorably treated with two intravitreal ranibizumab injections. A 79-year-old woman under coumadin treatment for atrial fibrillation experienced relapsing decreased vision in her left eye due to vitreous hemorrhage. She had had a past history of ocular hypertension corneal decompensation after phacoemulsification that required a Descemet Membrane Endothelial Keratoplasty and a subsequent trabeculectomy. After clearance of the hemorrhage, examination showed neovascularization not in the retina but surrounding the sclerostomy wound of the trabeculectomy, being diagnosed as a Swan syndrome. After two intravitreal injections of ranibizumab, gonioscopy showed complete resolution of the new vessels. No further recurrences have been reported and IOP has remained controlled without glaucomatous changes 7 months after the last injection. Clinical features and patient characteristics are described. Anti-vascular endothelial growth factor intravitreal injections may be a good and safe alternative to manage vitreous hemorrhage secondary to wound neovascularization of the trabeculectomy site.
Identifiants
pubmed: 35146202
doi: 10.1016/j.ajoc.2022.101332
pii: S2451-9936(22)00078-0
pmc: PMC8818482
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101332Informations de copyright
© 2022 Published by Elsevier Inc.
Déclaration de conflit d'intérêts
We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.
Références
Can J Ophthalmol. 1975 Jul;10(3):299-304
pubmed: 1148901
Trans Am Ophthalmol Soc. 1974;72:242-52
pubmed: 4477916
J Curr Glaucoma Pract. 2016 May-Aug;10(2):39-48
pubmed: 27536046
Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1976 Jan-Feb;81(1):OP138-44
pubmed: 1274035
Ophthalmic Surg. 1986 May;17(5):283-5
pubmed: 2425322
J AAPOS. 2001 Feb;5(1):55-7
pubmed: 11182676
Ophthalmology. 1989 Jan;96(1):50-3
pubmed: 2465521
J Cataract Refract Surg. 2009 Sep;35(9):1637-9
pubmed: 19683167
Ophthalmology. 1980 Jan;87(1):19-23
pubmed: 6154911
J Med Life. 2014;7 Spec No. 4:68-70
pubmed: 27057252
Ann Ophthalmol. 1978 Aug;10(8):1109-12
pubmed: 697284
Am J Ophthalmol. 2019 Aug;204:62-69
pubmed: 30862502
Am J Ophthalmol. 1999 Jul;128(1):98-100
pubmed: 10482102
Indian J Ophthalmol. 2020 Jun;68(6):1206-1209
pubmed: 32461484
Arch Ophthalmol. 1973 Feb;89(2):87-90
pubmed: 4734244
Can J Ophthalmol. 1987 Aug;22(5):271-5
pubmed: 2444319
Ophthalmic Surg. 1983 Mar;14(3):227-8
pubmed: 6682950
Exp Eye Res. 2016 Apr;145:412-416
pubmed: 26923799
Adv Ther. 2017 Feb;34(2):378-395
pubmed: 28000166
Int J Ophthalmol. 2015 Aug 18;8(4):697-702
pubmed: 26309865
BMC Res Notes. 2012 Oct 04;5:549
pubmed: 23035908
PLoS One. 2014 Feb 11;9(2):e88403
pubmed: 24523890
Int J Retina Vitreous. 2016 Nov 14;2:26
pubmed: 27895936
Korean J Ophthalmol. 2009 Sep;23(3):188-92
pubmed: 19794946